An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)

Journal of Neuro-Oncology

Volumn 123, Issue 1, 2015, Pages 85-91

  DeWire, Mariko ^a   Fouladi, Maryam ^a   Turner, David C ^b   Wetmore, Cynthia ^b   Hawkins, Cynthia ^c   Jacobs, Carmen ^d   Yuan, Ying ^d   Liu, Diane ^d   Goldman, Stewart ^e   Fisher, Paul ^f   Rytting, Michael ^d   Bouffet, Eric ^c   Khakoo, Yasmin ^g   Hwang, Eugene I ^h   Foreman, Nicholas ⁱ   Stewart, Clinton F ^b   Gilbert, Mark R ^d   Gilbertson, Richard ^b   Gajjar, Amar ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e CHILDREN'S MEMORIAL HOSPITAL   (United States)

^f LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

ⁱ CHILDREN S HOSPITAL COLORADO   (United States)

Author keywords

Bevacizumab; Children; Lapatinib; Recurrent ependymoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; CREATINE KINASE; LAPATINIB; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTERY THROMBOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DESQUAMATION; DIARRHEA; DIGESTIVE SYSTEM DISEASE; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TOLERABILITY; EOSINOPHILIA; EPENDYMOMA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL LEAK; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INFECTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIVER TOXICITY; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; RASH; RECURRENT DISEASE; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VEIN THROMBOSIS; VOMITING; WOUND DEHISCENCE; CANCER STAGING; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; FOLLOW UP; MULTICENTER STUDY; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; TISSUE DISTRIBUTION; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; EPENDYMOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; QUINAZOLINES; SALVAGE THERAPY; SURVIVAL RATE; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84930216566     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1764-7     Document Type: Article

References (17)

1. Messahel B, Ashley S, Saran F, Ellison D, Ironside J, Phipps K, Cox T, Chong WK, Robinson K, Picton S, Pinkerton CR, Mallucci C, Macarthur D, Jaspan T, Michalski A, Grundy RG, CsCLGBT Committee (2009) Relapsed intracranial ependymoma in children in the UK: patterns of relapse, survival and therapeutic outcome. Eur J Cancer 45(10):1815–1823. doi:10.1016/j.ejca.2009.03.018
2. Zacharoulis S, Ashley S, Moreno L, Gentet JC, Massimino M, Frappaz D (2010) Treatment and outcome of children with relapsed ependymoma: a multi-institutional retrospective analysis. Childs Nerv Syst 26(7):905–911. doi:10.1007/s00381-009-1067-4
3. Gilbertson RJ, Bentley L, Hernan R, Junttila TT, Frank AJ, Haapasalo H, Connelly M, Wetmore C, Curran T, Elenius K, Ellison DW (2002) ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 8(10):3054–3064
4. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Molecular cancer therapeutics 1(2):85–94
5. Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ (2010) Phase I trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol 28(27):4221–4227. doi:10.1200/JCO.2010.28.4687
6. Korshunov A, Golanov A, Timirgaz V (2002) Immunohistochemical markers for prognosis of ependymal neoplasms. J Neurooncol 58(3):255–270
7. Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P, Magdaleno S, Dalton J, Calabrese C, Board J, Macdonald T, Rutka J, Guha A, Gajjar A, Curran T, Gilbertson RJ (2005) Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8(4):323–335. doi:10.1016/j.ccr.2005.09.001
8. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11(1):69–82. doi:10.1016/j.ccr.2006.11.020
9. Rich JN, Sathornsumetee S, Keir ST, Kieran MW, Laforme A, Kaipainen A, McLendon RE, Graner MW, Rasheed BK, Wang L, Reardon DA, Ryan AJ, Wheeler C, Dimery I, Bigner DD, Friedman HS (2005) ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res 11(22):8145–8157. doi:10.1158/1078-0432.CCR-05-0319
10. Green RM, Cloughesy TF, Stupp R, DeAngelis LM, Woyshner EA, Ney DE, Lassman AB (2009) Bevacizumab for recurrent ependymoma. Neurology 73(20):1677–1680. doi:10.1212/WNL.0b013e3181c1df34
11. Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN (2012) A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 134(1):13–20. doi:10.1007/s10549-011-1918-z
12. Bai F, Freeman BB, Fraga CH, Fouladi M, Stewart CF (2006) Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS). J Chromatogr B 831(1–2):169–175. doi:10.1016/j.jchromb.2005.11.044
13. Gururangan S, Fangusaro J, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Gajjar A, Goldman S, Friedman HS, Packer RJ, Boyett JM, Kun LE, McLendon R (2012) Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma—a pediatric brain tumor consortium study. Neuro Oncol 14(11):1404–1412. doi:10.1093/neuonc/nos213
14. Bouffet E, Capra M, Bartels U (2009) Salvage chemotherapy for metastatic and recurrent ependymoma of childhood. Childs Nerv Syst 25(10):1293–1301. doi:10.1007/s00381-009-0883-x
15. Merchant TE, Boop FA, Kun LE, Sanford RA (2008) A retrospective study of surgery and reirradiation for recurrent ependymoma. Int J Radiat Oncol Biol Phys 71(1):87–97. doi:10.1016/j.ijrobp.2007.09.037
16. Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Goldman S, Geyer JR, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ (2013) A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Neurooncol 114(2):173–179. doi:10.1007/s11060-013-1166-7
17. Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, Cooney-Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM, Blaney SM, Kandel JJ, Yamashiro DJ, Study CsOG (2008) Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a children’s oncology group study. J Clin Oncol 26(3):399–405. doi:10.1200/JCO.2007.11.9230